Literature DB >> 21463069

Examining the use of tramadol hydrochloride as an antidepressant.

Justin Barber1.   

Abstract

Tramadol (Ultram, Ultracet) is a centrally acting synthetic opioid with analgesic efficacy comparable to codeine. Antinociception is attributed to low but effective affinity for the mu-opioid receptor (μ), as well as reuptake inhibition of the monoamines norepinephrine (NE) and serotonin (5HT). Dual action antidepressants mirtazapine (Remeron), duloxetine (Cymbalta), and most notably venlafaxine (Effexor), which tramadol is closely related to in structure, also inhibit NE and 5HT reuptake. These medications are proven effective antidepressants and this shared monoaminergic action resulted in the research of tramadol as a potential treatment for depression. The present article intends to substantiate the use of tramadol in this manner by analyzing several decades of research which is presented as an illustration of neuronal theories, as well as lab work and case studies of both the supporting ideas and potential hazards. Finally, the article promotes the benefits of acute action in comparison to modern antidepressants and the documentation of low abuse rates while maintaining an object view of the risks, most notably, the risk for addiction from agonist action on μ-receptors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463069     DOI: 10.1037/a0022721

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  16 in total

1.  Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining Analysis from the Patients' Perspective.

Authors:  John A Bumpus
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-29

2.  Design, synthesis and biological evaluation of N-phenylalkyl-substituted tramadol derivatives as novel μ opioid receptor ligands.

Authors:  Qing Shen; Yuan-yuan Qian; Xue-jun Xu; Wei Li; Jing-gen Liu; Wei Fu
Journal:  Acta Pharmacol Sin       Date:  2015-06-08       Impact factor: 6.150

3.  Multiple suicide attempts associated with addiction to tramadol.

Authors:  Bénédicte Nobile; Marine Bonnin; Emilie Olié; Philippe Courtet
Journal:  Ann Gen Psychiatry       Date:  2022-07-01       Impact factor: 3.301

4.  Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression.

Authors:  Seham Alaiyed; Mondona McCann; Gouri Mahajan; Grazyna Rajkowska; Craig A Stockmeier; Kenneth J Kellar; Jian Young Wu; Katherine Conant
Journal:  J Neurosci       Date:  2020-04-08       Impact factor: 6.167

5.  Tramadol reinforces antidepressant effects of ketamine with increased levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in rat hippocampus.

Authors:  Chun Yang; Xiaomin Li; Nan Wang; Shixia Xu; Jianjun Yang; Zhiqiang Zhou
Journal:  Front Med       Date:  2012-11-03       Impact factor: 4.592

Review 6.  Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?

Authors:  Eun Jung Chang; Eun Ji Choi; Kyung Hoon Kim
Journal:  Korean J Pain       Date:  2016-07-01

7.  Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders.

Authors:  Yu Sun; Vaibhav A Narayan; Gayle M Wittenberg
Journal:  BMC Pharmacol Toxicol       Date:  2016-10-21       Impact factor: 2.483

8.  EEG and Sleep Effects of Tramadol Suggest Potential Antidepressant Effects with Different Mechanisms of Action.

Authors:  Szabolcs Koncz; Noémi Papp; Noémi Menczelesz; Dóra Pothorszki; György Bagdy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-04

9.  Tramadol pretreatment enhances ketamine-induced antidepressant effects and increases mammalian target of rapamycin in rat hippocampus and prefrontal cortex.

Authors:  Chun Yang; Wen-Yuan Li; Hai-Yin Yu; Zhi-Qin Gao; Xiang-Liu Liu; Zhi-Qiang Zhou; Jian-Jun Yang
Journal:  J Biomed Biotechnol       Date:  2012-04-08

10.  Effect of Tramadol/Acetaminophen on Motivation in Patients with Chronic Low Back Pain.

Authors:  Tomoko Tetsunaga; Tomonori Tetsunaga; Masato Tanaka; Keiichiro Nishida; Yoshitaka Takei; Toshifumi Ozaki
Journal:  Pain Res Manag       Date:  2016-03-02       Impact factor: 3.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.